MedTrace Logo

ADX10059 as a Monotherapy in Patients With Gastroesophageal Reflux (GERD)

NCT00820079 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2009-12-24

No results posted yet for this study

Summary

Evaluation of the effect of ADX10059 on symptom control in patients with gastroesophageal reflux.

Conditions

  • Gastroesophageal Reflux

Interventions

DRUG

ADX10059

oral administration

DRUG

ADX10059 Matching Placebo

oral administration

Sponsors & Collaborators

  • Addex Pharma S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2009-10-31

Countries

  • Austria
  • Belgium
  • France
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00820079 on ClinicalTrials.gov